Nureca Limited has officially resubmitted a more legible copy of the Notice of its 10th Annual General Meeting (AGM) and the Annual Report for the fiscal year 2025-26. This resubmission, dated July 8, 2026, follows an earlier submission on July 3, 2026, and is intended for the convenience of the stock exchanges and shareholders. The company emphasized that the content of the disclosure remains unchanged, with no modifications to the previously submitted information. The resubmission is purely to provide a clearer and more readable version of the documents. The Annual Report 2025-26 itself details various aspects of the company's operations and performance. It includes a Chairman's Message highlighting the strategic shift towards 'Make in India' manufacturing, focusing on quality, innovation, and accessibility for Indian consumers. The report outlines Nureca's D2C growth strategy, its expanding online presence, and the development of its connected health solutions and manufacturing base. It also provides an overview of the global and Indian home healthcare market, discussing opportunities and threats, and segment-wise performance. Financially, for the year ended March 31, 2026, Nureca reported a significant increase in revenue from operations, up 34.02% to ₹1469.93 million from ₹1096.61 million in FY25. EBITDA also saw a substantial rise of 68.94% to ₹82.78 million from ₹49 million in FY25, with EBITDA margin improving to 5.63% from 4.46%. Profit After Tax (PAT) grew by 146.10% to ₹20.82 million from ₹8.46 million in FY25. The company's net worth decreased due to a share buyback, but the return on average capital employed increased to 3.59% from 1.04%. The report also mentions a total of 154 employees as of March 31, 2026.
